3,194 Shares in Gilead Sciences, Inc. (GILD) Acquired by AE Wealth Management LLC
AE Wealth Management LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, HoldingsChannel reports. The firm acquired 3,194 shares of the biopharmaceutical company’s stock, valued at approximately $259,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. FMR LLC raised its stake in shares of Gilead Sciences by 1.1% during the 2nd quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after buying an additional 258,005 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 2.4% during the 2nd quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after buying an additional 2,148,697 shares in the last quarter. Northern Trust Corp raised its stake in shares of Gilead Sciences by 0.7% during the 2nd quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after buying an additional 116,780 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of Gilead Sciences by 19.0% during the 2nd quarter. Toronto Dominion Bank now owns 472,577 shares of the biopharmaceutical company’s stock worth $33,445,000 after buying an additional 75,364 shares in the last quarter. Finally, Fagan Associates Inc. raised its stake in shares of Gilead Sciences by 2.6% during the 2nd quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 845 shares in the last quarter. 75.95% of the stock is owned by hedge funds and other institutional investors.
In other Gilead Sciences news, EVP James R. Meyers sold 100,000 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $80.24, for a total transaction of $8,024,000.00. Following the sale, the executive vice president now owns 102,715 shares in the company, valued at approximately $8,241,851.60. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider John C. Martin sold 73,333 shares of the stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $75.13, for a total value of $5,509,508.29. Following the sale, the insider now owns 3,070,099 shares in the company, valued at approximately $230,656,537.87. The disclosure for this sale can be found here. In the last quarter, insiders have sold 591,666 shares of company stock worth $44,466,567. 1.30% of the stock is owned by insiders.
Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s quarterly revenue was down 13.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.75 EPS. equities research analysts forecast that Gilead Sciences, Inc. will post 8.48 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date of this dividend was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.
A number of brokerages have recently issued reports on GILD. Zacks Investment Research downgraded Gilead Sciences from a “hold” rating to a “sell” rating in a research note on Thursday. Leerink Swann increased their target price on Gilead Sciences from $84.00 to $85.00 and gave the stock a “market perform” rating in a research note on Thursday, October 19th. Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a research note on Wednesday. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, October 19th. Finally, Mizuho increased their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have assigned a buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average target price of $85.53.
COPYRIGHT VIOLATION WARNING: “3,194 Shares in Gilead Sciences, Inc. (GILD) Acquired by AE Wealth Management LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2018/01/20/3194-shares-in-gilead-sciences-inc-gild-acquired-by-ae-wealth-management-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.